References
- Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al. A placobo-controlled double-blind randomized trial in patients with amyotrophic lateral sclerosis with creatine monohydrate: a randomized sequential trial. Ann Neurol. 2003;53:437–45.
- Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al.;Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
- Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomized sequential trial. J Neurol Neurosurg Psychiatry. 2012;83: 557–64.
- UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase III multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurology. 2013;12:339–45.
- Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al.; QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
- Coffey CS.Adaptive Design Across Stages of Therapeutic Development. In: Ravina B, Cummings J, McDermott M, Poole RM. Clinical Trials in Neurology: Design, Conduct, and Analysis. Cambridge: Cambridge University Press; 2012. pp 91–100.
- Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs: background operational aspects and examples. Drug Inf J. 2006;40: 463–73.
- Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, et al., Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013;8:e61177
- NeuroNEXT.org http://www.neuronext.org/ Viewed online 23 July 2013.
- Prize4Life Announces $50,000 ALS Prediction Prize Winners. http://www.prize4life.org/page/news/10194. Viewed online 23 July 2013.
- Wang SJ, Hung HMJ, O’Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biometrical J. 2009;51: 358–74.
- Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063–87.
- Gooch CL, Shefner JM. ALS surrogate markers. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5 (Suppl 1):104–7.
- Neuwirth C, Nandedkar S, Stålberg E, Barkhaus PE, Carvalho MD, Furtula J, et al. Motor Unit Number Index (MUNIX): reference values of five different muscles in healthy subjects from a multicentre study. Clin Neurophysiol. 2011;122:1895–8.
- Rutkove SB, Zhang H, Schoenfeld DA, Raynor EM, Shefner JM, Cudkowicz ME, et al. Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol. 2007;118:2413–8.
- Morgan P, van der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419–24.
- Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007;6:1045–53.